Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient
Open Access
- 16 September 2025
- journal article
- case report
- Published by Wiley in Cancer Reports
- Vol. 8 (9) , e70349
Abstract
Background: Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit.Case: An 80‐year‐old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B‐cell lymphoma‐type RS (DLBCL‐RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third‐line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID‐19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.Conclusion: This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL‐RS.Keywords
This publication has 14 references indexed in Scilit:
- Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyJournal of Clinical Oncology, 2024
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024Journal of the National Comprehensive Cancer Network, 2024
- Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialJournal of Clinical Oncology, 2023
- Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyJournal of Clinical Oncology, 2022
- The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitorHaematologica, 2020
- Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single centerHaematologica, 2019
- Biology and treatment of Richter syndromeBlood, 2018
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLBlood, 2018
- A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factorBritish Journal of Haematology, 2017
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBlood, 2016